Sort
48,018 grants matching “immunotherapy”
Viral oncoprotein targeted immune therapy for Merkel cell carcinoma
$621,892Paul Nghiem · University Of Washington · R01 · FY2014 · CA
preclinical optimization of BCMA directed T cell therapy
$621,878Marta Chesi · Mayo Clinic Arizona · R01 · FY2023 · CA
preclinical optimization of BCMA directed T cell therapy
$621,878Marta Chesi · Mayo Clinic Arizona · R01 · FY2025 · CA
Glycosylation and Immune Evasion in Urologic Tumors
$621,878Sharon Pitteri · Stanford University · U01 · FY2019 · CA
Anti-tumor immunity and intestinal microbiota are modulated by mitochondrial DNA
$621,794Douglas C Wallace · Children'S Hosp Of Philadelphia · R01 · FY2023 · CA
T cell immunity in a rare juvenile form of motor neuron disease
$621,769Ivan Marazzi · University Of California-Irvine · R01 · FY2024 · NS
Exploiting and enhancing IgE-binding epitopes of the 2S albumins of peanuts and tree nuts
$621,743Stephen C. Dreskin · University Of Colorado Denver · R01 · FY2024 · AI
Resistance mechanisms to autophagy-modulating therapies
$621,660Ravi K Amaravadi · University Of Pennsylvania · R01 · FY2024 · CA
ECOG-ACRIN Thoracic Malignancies Integrated Translational Science Center
$621,608Ticiana Leal · Emory University · UG1 · FY2023 · CA
Ovarian Cancer Epigenetics, Immunity and Therapy
$621,601Weiping Zou · University Of Michigan At Ann Arbor · R01 · FY2020 · CA
A single-arm phase II study to evaluate the safety and efficacy of combination systematic chemotherapy and multiple rounds of endoscopic ultrasound-guided radiofrequency ablation in pancreatic cancer
$621,551Nirav Thosani · University Of Texas Hlth Sci Ctr Houston · R01 · FY2024 · CA
Combating melanoma with an attenuated bacterial therapeutic
$621,545Jianxun Jim Song · Texas A&M University Health Science Ctr · R01 · FY2023 · CA
A Novel Strategy Targeting TfR1 for the Prevention/Treatment of AIDS-related NHL
$621,421Manuel L Penichet · University Of California Los Angeles · R01 · FY2019 · CA
(PQ#3) Novel tumor intrinsic PD-L1 signals direct tumor immune cell infiltration
$621,419Tyler J. Curiel · University Of Texas Hlth Science Center · R01 · FY2019 · CA
Molecular Epidemiology of non-Hodgkin Lymphoma Survival
$621,417James R Cerhan · Mayo Clinic Rochester · R01 · FY2010 · CA
Targeting Alloreactivity for Leukemia Eradication
$621,411Stanley R Riddell · Fred Hutchinson Cancer Research Center · P01 · FY2008 · CA
Reducing Cancer Transcriptional Heterogeneity through Regulation of Chromatin Structure
$621,362Vadim Backman · Northwestern University · R01 · FY2019 · CA
Phase 0-1 Clinical Trials
$621,311James Doroshow · Division Of Basic Sciences - Nci · ZIA · FY2022 · CA
Training Program in Basic Cancer Research
$621,245Wistar Institute · T32 · FY2002 · CA
Chemoimmunoprevention of EGFR-Driven Non-Small Cell Lung Cancer
$621,239Ming You · Medical College Of Wisconsin · R01 · FY2019 · CA
Safety and Feasibility of Cultivated Autologous Limbal Epithelial Cell (CALEC) Transplantation in the Treatment of Limbal Stem Cell Deficiency
$621,211Jerome Ritz · Dana-Farber Cancer Inst · UG1 · FY2017 · EY
Design principles for engineering therapeutic macrophages
$621,158Jason Hung-Ying Yang · Rutgers Biomedical And Health Sciences · R21 · FY2025 · EB
Imaging Modulation of Immune Phenotype
$621,116Katherine W Ferrara · Stanford University · R01 · FY2024 · CA
Linking insertional mutagenesis and cell function to improve CAR T cell therapy
$621,091Frederic D Bushman · University Of Pennsylvania · R01 · FY2021 · CA
A Phase 1 Clinical Trial Evaluating the Novel Small Molecule Immuno-Oncology Antagonist SX-682 Alone and With Pembrolizumab in Metastatic Melanoma
$621,000Stuart J Kahn · Syntrix Biosystems, Inc. · R44 · FY2017 · CA